BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. The Company will report results from this trial and host a call with study clinical cardiology leadership to review the opportunity, early positive results, and ra

Touchlight, a biotechnology CDMO pioneering enzymatic DNA production has been awarded a second grant from the Office of Naval Research (ONR) and the Defence Science and Technology Laboratory (Dstl) to continue work with Professor Shelley Minteer's research group, Missouri University of Science and Technology, to further propel the development of DNA-enabled biobatteries. Biobatteries use enzymes to generate electricity from the breakdown of complex fuels, such as carbohydrates,

Nordic Bioproducts Group (NBG), a leader in biomaterial innovation and developer of proprietary AaltoCell™ Technology, announces the opening of its commercial-scale production facility for microcrystalline cellulose (MCC) and other cellulose derivatives in Lappeenranta, Finland. This first-of-its-kind facility represents a significant leap in manufacturing and enabling continuous and sustainable production at scale. Featuring the world's first continuous production line of

Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertexhas received an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem TM , to... To optimize production of Vertex' cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will work together to further expand TreeFrog's process for producing and growing cells for Vertex's T1D therapies. TreeFrog's proprietary technology platform C-Stem™

Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne). Sevasemten is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage. Sevasemten is currently in late-stage clinical trials for individuals

ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven global pharmaceutical company Boehringer Ingelheim is adopting the transformative new functionality of LifeSphere® Clarity™. LifeSphere Clarity picks up where traditional signal detection ends, providing access to knowledge graphs, association graphs, medical case clustering, and more advanced capabilities to drive better understanding the &ldquo

Krystal Biotech, Inc., a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with locally advanced or metastatic solid tumors of the lung. “Cytokine therapy holds significant potential for the treatment of solid tum

SynOx Therapeutics Limited, the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of Tenosynovial Giant Cell Tumour (TGCT). TGCT is a